Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 (COVID-19) Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout.
Alexandra N LeaWendy A LeydenOleg SofryginBen J MarafinoJacek SkarbinskiSonia NapravnikDeana AgilMichael AugenbraunLorie BenningMichael A HorbergCeleena JeffersonVincent C MarconiLesley S ParkKirsha S GordonLisa BastaracheSrushti GangireddyKeri N AlthoffSally B CoburnKelly A GeboRaynell LangCarolyn WilliamsMichael J SilverbergPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
Before COVID-19 vaccine availability, PWH were at greater risk for severe outcomes than PWoH. Tenofovir was associated with a significant reduction in clinical events for both PWH and PWoH.